Libivirumab

Libivirumab^?
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Hepatitis B surface antigen
Clinical data
Identifiers
CAS Registry Number	569658-79-3^N
ATC code	None
Chemical data
Formula	C₆₅₉₈H₁₀₂₃₂N₁₇₈₈O₂₀₆₀S₄₆
Molecular mass	149.04 kDa
N (what is this?) (verify)

Libivirumab is a human monoclonal antibody directed against the hepatitis B virus.^[1]^[2]

References

↑ WHO Drug Information
↑ Shouval, D et al. (2006). "Anti-Viral Effects, Pharmacokinetics and Safety of Two Human Monoclonal Anti-Hbs (Libivirumab/Exbivirumab) Versus Hepatitis B Immune Globulin (Hbig) in Hepatits B Virus (Hbv) in Liver Transplant (Lt) Recipients". Hepatology 44 (4): 188A–700A [196A]. doi:10.1002/hep.21395. PMID 17001593.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab

Viral ("-vi(r)-")

Human ("-viru-")	Exbivirumab Foravirumab Libivirumab Rafivirumab Regavirumab Sevirumab Tuvirumab

Humanized ("-vizu-")	Felvizumab Motavizumab Palivizumab Suvizumab

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab Raxibacumab

Mouse ("-baco-")	Edobacomab

Chimeric ("-baxi-")	Pagibaximab

Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Human ("-toxu-")	Actoxumab Bezlotoxumab

Humanized ("-toxazu-")	Urtoxazumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III